comparemela.com

Page 26 - Replimune Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Asher Bio Appoints Andrea Pirzkall, M D , as Chief Medical Officer

Industry veteran brings deep expertise in translational medicine and clinical development in oncologySAN FRANCISCO (BUSINESS WIRE) Asher Biotherapeutics, Inc. (Asher Bio), a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced the appo.

Replimune Group (REPL) – Investment Analysts Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of Replimune Group (NASDAQ: REPL) recently: 5/25/2022 – Replimune Group was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes […]

Replimune Announces the Departure of Jason Rhodes from its Board of Directors

Replimune Announces the Departure of Jason Rhodes from its Board of Directors
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

Replimune Group, Inc (NASDAQ:REPL) to Post FY2024 Earnings of ($2 77) Per Share, Wedbush Forecasts

Replimune Group, Inc. (NASDAQ:REPL – Get Rating) – Analysts at Wedbush issued their FY2024 earnings per share estimates for shares of Replimune Group in a research note issued to investors on Tuesday, May 24th. Wedbush analyst R. Driscoll anticipates that the company will earn ($2.77) per share for the year. Wedbush currently has a “Outperform” […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.